Shares of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) have received a consensus recommendation of “Buy” from the eleven analysts that are covering the company. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock opened at $24.51 in last session, and closed at $23.93, while the day range of ACAD stock is $23.87 – $24.85. The stock showed a positive weekly performance of 1.96%.
Based in Taipei, PharmaEngine will receive US$75 million in the advance payment from US-based Merrimack Pharmaceuticals Inc (NASDAQ:MACK) in the fourth quarter this year after securing a drug permit for MM-398 in the US, the brokerage said. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock opened at $4.91, in last session and closed at $4.87, by losing -0.81%. The 52 week range of MACK is $2.05 – $7.09. Company’s market capitalization is $498.43million.
Pomerantz LLP has filed a class action lawsuit against Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and certain of its officers. Sarepta Therapeutics Inc (NASDAQ:SRPT) stock decreased -1.65% and finished the last session at $26.16. The EPS of the stock remained -5.52. Company’s market capitalization is $983.15million.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) was a big mover last session, as its shares rose over 19% on the day. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) stock opened the session at $11.75, and closed the session at $11.44. The 52 week range of the CNAT stock remained $5.76 – $15.67 and the day range was $11.13 – $12.44.